摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(4-aminophenoxy)acetic acid hydrochloride | 162221-06-9

中文名称
——
中文别名
——
英文名称
(4-aminophenoxy)acetic acid hydrochloride
英文别名
(4-amino-phenoxy)-acetic acid hydrochloride;4-aminophenoxy-acetic acid hydrochloride;(4-Amino-phenoxy)-acetic acid HCl;(4-Amino-phenoxy)acetic acid HCl;2-(4-Aminophenoxy)acetic acid hydrochloride;2-(4-aminophenoxy)acetic acid;hydrochloride
(4-aminophenoxy)acetic acid hydrochloride化学式
CAS
162221-06-9
化学式
C8H9NO3*ClH
mdl
——
分子量
203.625
InChiKey
OSMOKKCONNJAPZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.15
  • 重原子数:
    13
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    72.6
  • 氢给体数:
    3
  • 氢受体数:
    4

SDS

SDS:fead7e4a9827b03c25cad3c03a36530b
查看

反应信息

  • 作为反应物:
    描述:
    (4-aminophenoxy)acetic acid hydrochloridepotassium carbonate 作用下, 以 为溶剂, 反应 1.0h, 以81%的产率得到4-胺苯氧基乙酸
    参考文献:
    名称:
    第一种(4-氨基苯氧基)链烷酸基三足三聚氰胺的收敛与发散三步合成
    摘要:
    摘要 从 N-(4-羟基苯基)乙酰胺(扑热息痛,收敛法)或氰尿酰氯与 4-氨基苯酚反应(发散法)开始,两条合成路线向新型三足 N-取代三聚氰胺作为(4 -氨基苯氧基)乙酸或4-(4-氨基苯氧基)丁酸是比较定义的。关键步骤包括 4-氨基苯酚的 N-掩蔽形式的威廉姆森醚化和 N-和/或 O-保护的(4-氨基苯氧基)链烷烃链段的酸性水解。图形概要
    DOI:
    10.1080/00397911.2015.1041048
  • 作为产物:
    描述:
    4-乙酰氨基苯乙酸乙酯盐酸 作用下, 以 为溶剂, 反应 2.0h, 以92%的产率得到(4-aminophenoxy)acetic acid hydrochloride
    参考文献:
    名称:
    第一种(4-氨基苯氧基)链烷酸基三足三聚氰胺的收敛与发散三步合成
    摘要:
    摘要 从 N-(4-羟基苯基)乙酰胺(扑热息痛,收敛法)或氰尿酰氯与 4-氨基苯酚反应(发散法)开始,两条合成路线向新型三足 N-取代三聚氰胺作为(4 -氨基苯氧基)乙酸或4-(4-氨基苯氧基)丁酸是比较定义的。关键步骤包括 4-氨基苯酚的 N-掩蔽形式的威廉姆森醚化和 N-和/或 O-保护的(4-氨基苯氧基)链烷烃链段的酸性水解。图形概要
    DOI:
    10.1080/00397911.2015.1041048
点击查看最新优质反应信息

文献信息

  • Functionalized drugs and polymers derived therefrom
    申请人:Bezwada S. Rao
    公开号:US20060172983A1
    公开(公告)日:2006-08-03
    Compounds selected from: where DRUG-OH, DRUG-COOH and DRUG-NH 2 are biologically active compounds; each X is independently selected from —CH 2 COO— (glycolic acid moiety), —CH(CH 3 )COO— (lactic acid moiety), —CH 2 CH 2 OCH 2 COO— (dioxanone moiety), —CH 2 CH 2 CH 2 CH 2 CH 2 COO— (caprolactone moiety), —(CH 2 ) y COO—, where y is 2-4 or 6-24 and —(CH 2 CH 2 O) z CH 2 COO—, where z is 2-24; each Y is independently selected from —COCH 2 O— (glycolic ester moiety), —COCH(CH 3 )O— (lactic ester moiety), —COCH 2 OCH 2 CH 2 O— (dioxanone ester moiety), —COCH 2 CH 2 CH 2 CH 2 CH 2 O— (caprolactone ester moiety), —CO(CH 2 ) m O—, where m is 2-4 or 6-24 and —COCH 2 O(CH 2 CH 2 O) n — where n is between 2-24; R′ is hydrogen, benzyl or an alkyl group, the alkyl group being either straight-chained or branched; and p is 1-6. Multi-functional compounds and drug dimers, oligomers and polymers are also disclosed.
    从中选择的化合物:其中DRUG-OH,DRUG-COOH和DRUG-NH2是生物活性化合物;每个X独立地从—CH2COO—(乙二酸基团),—CH(CH3)COO—(乳酸基团),—CH2CH2OCH2COO—(二氧杂环己酮基团),—CH2CH2CH2CH2CH2COO—(己内酯基团),—(CH2)yCOO—中选择,其中y为2-4或6-24和—(CH2CH2O)zCH2COO—,其中z为2-24;每个Y独立地从—COCH2O—(乙二酸酯基团),—COCH(CH3)O—(乳酸酯基团),—COCH2OCH2CH2O—(二氧杂环己酮酯基团),—COCH2CH2CH2CH2CH2O—(己内酯酯基团),—CO(CH2)mO—,其中m为2-4或6-24和—COCH2O(CH2CH2O)n—,其中n为2-24;R′为氢,苄基或烷基,烷基可以是直链或支链;p为1-6。还披露了多功能化合物和药物二聚体、寡聚体和聚合物。
  • FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM
    申请人:Bezwada Rao S.
    公开号:US20090170927A1
    公开(公告)日:2009-07-02
    The present invention relates to compounds of formula I, which are functionalized phenolic compounds, and polymers formed from the same. Ar—[O—(X) p —R′] q I Polymers formed from the functionalized phenolics are expected to have controllable degradation profiles, enabling them to release an active component over a desired time range. The polymers are also expected to be useful in a variety of medical applications.
    本发明涉及公式I的化合物,这些化合物是官能化酚类化合物,以及由它们形成的聚合物。从官能化酚类化合物形成的聚合物预计具有可控的降解特性,使它们能够在所需的时间范围内释放活性成分。这些聚合物还预计在各种医疗应用中有用。
  • THIAZOLIDINE DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF
    申请人:Kim Sung Soo
    公开号:US20100048570A1
    公开(公告)日:2010-02-25
    The present invention relates to novel 2-carbonyl-3-acyl-1,3-thiazolidines having a β-amino group on the acyl chain, in free, prodrug form or pharmaceutically acceptable salt thereof, including their enantiomers, diastereomers and racemates, as efficient inhibitors against DPP-IV. The invention further relates to the pharmaceutical compositions comprising the disclosed compounds. The present invention also relates to methods for preparing the disclosed compounds and for treating DPP-IV-mediated diseases.
    本发明涉及具有β-氨基团的酰基链上的新型2-羰基-3-酰基-1,3-噻唑啉化合物,包括其自由形式、前药形式或其药用可接受盐,包括它们的对映体、异构体和消旋体,作为高效的DPP-IV抑制剂。该发明还涉及包含所述化合物的药物组合物。本发明还涉及制备所述化合物以及治疗DPP-IV介导的疾病的方法。
  • Condensed 4-aminopyridines with antirheumatic activity
    申请人:Knoll Aktiengesellschaft
    公开号:US05780482A1
    公开(公告)日:1998-07-14
    Compounds of formula I ##STR1## and pharmaceutically acceptable salts thereof in which one of A or B represents N and the other represents N or C--R.sub.3 ; R.sub.1 represents hydrogen, halo, alkyl, hydroxy, carboxyalkenyl, alkoxycarbonylalkenyl, hydroxyalkyl, carboxyalkyl, alkoxycarbonylalkyl, alkoxy, halogenated alkyl, carboxy, alkoxycarbonyl, alkanoylamino or carbamoylalkenyl; R.sub.2 represents hydrogen, alkyl, halo, alkoxy, hydroxy, alkanoyloxy, or phenoxy; R.sub.3 represents hydrogen or alkyl; R.sub.4 represents hydrogen, halo, alkoxycarbonyl, cyano, benzyloxycarbonyl, alkanoyl, benzoyl, alkyl, carboxy, alkylthio or carbamoyl; R.sub.5 represents hydrogen or alkyl; R.sub.9 represents hydrogen or alkyl; R.sub.10 represents phenyl, pyridyl or pyrimidinyl substituted by OR.sub.6 and optionally further substituted wherein R.sub.6 represents hydrogen, alkyl, alkoxycarbonyl or carbamoyl, alicyclic hydrocarbon, phenyl, cycloalkylalkyl, arylalkyl or pyridyl; or when R.sub.10 represents phenyl, OR.sub.6 represents a monosaccharide group or a disaccharide group; which are antirheumatic agents. Compositions containing these compounds and processes to prepare them are also disclosed.
    化学式I的化合物及其药学上可接受的盐,其中A或B中的一个代表N,另一个代表N或C--R.sub.3;R.sub.1代表氢、卤素、烷基、羟基、羧烯基、烷氧羰基烯基、羟基烷基、羧基烷基、烷氧羰基烷基、烷氧基、卤代烷基、羧基、烷氧羰基、烷酰胺基或氨基烯基;R.sub.2代表氢、烷基、卤素、烷氧基、羟基、烷酰氧基或苯氧基;R.sub.3代表氢或烷基;R.sub.4代表氢、卤素、烷氧羰基、氰基、苄氧羰基、烷酰基、苯甲酰基、烷基、羧基、烷硫基或氨基甲酰;R.sub.5代表氢或烷基;R.sub.9代表氢或烷基;R.sub.10代表苯基、吡啶基或嘧啶基,被OR.sub.6取代,并且可选择进一步取代,其中R.sub.6代表氢、烷基、烷氧羰基或氨基,脂环烃、苯基、环烷基烷基、芳基烷基或吡啶基;或当R.sub.10代表苯基时,OR.sub.6代表单糖基或双糖基;这些化合物是抗风湿药物。揭示了含有这些化合物的组合物和制备它们的方法。
  • Bioabsorbable and biocompatible polyurethanes and polyamides for medical devices
    申请人:S. Bezwada Rao
    公开号:US20060188547A1
    公开(公告)日:2006-08-24
    Absorbable polyurethanes, polyamides and polyester urethanes prepared from at least one compound selected from: or the diamines and diisocyanates thereof, wherein each X represents a member independently selected from —CH 2 COO— (glycolic acid moiety), —CH(CH 3 )COO— (lactic acid moiety), —CH 2 CH 2 OCH 2 COO— (dioxanone), —CH 2 CH 2 CH 2 CH 2 CH 2 COO— (caprolactone moiety), —(CH 2 ) y COO— where y is one of the numbers 2, 3, 4 or 6-24 inclusive, and —(CH 2 CH 2 O) z′ CH 2 COO— where z′ is an integer between 2 and 24, inclusive; each Y represents a member independently selected from —COCH 2 O— (glycolic ester moiety), —COCH(CH 3 )O— (lactic ester moiety), —COCH 2 OCH 2 CH 2 O— (dioxanone ester), —COCH 2 CH 2 CH 2 CH 2 CH 2 O— (caprolactone ester), —CO(CH 2 ) m O— where m is an integer between 2, 3, 4 or 6-24 inclusive, —COCH 2 O(CH 2 CH 2 O) n — where n is an integer between 2 and 24, inclusive; R′ is hydrogen, benzyl or an alkyl group, the alkyl group being either straight-chained or branched; p is an integer between 1 and 4, inclusive; and Rn represents one or more members selected from H, alkoxy, benzyloxy, aldehyde, halogen, carboxylic acid and —NO 2 , which is attached directly to an aromatic ring or attached through an aliphatic chain. Absorbable polymers prepared from these compounds are useful for drug delivery, tissue engineering, tissue adhesives, adhesion prevention and other implantable medical devices.
    由至少选择自以下化合物制备的可吸收聚氨酯、聚酰胺和聚酯聚氨酯:或其二胺和二异氰酸酯,其中每个X分别代表从—CH2COO—(乙二醇酸基团),—CH(CH3)COO—(乳酸酸基团),—CH2CH2OCH2COO—(二氧环己酮),—CH2CH2CH2CH2CH2COO—(己内酯基团),—(CH2)yCOO—其中y是2、3、4或6-24之间的一个数字,以及—(CH2CH2O)z′CH2COO—其中z′是介于2和24之间的整数;每个Y分别代表从—COCH2O—(乙二醇酸酯基团),—COCH(CH3)O—(乳酸酸酯基团),—COCH2OCH2CH2O—(二氧环己酮酯基团),—COCH2CH2CH2CH2CH2O—(己内酯酯基团),—CO(CH2)mO—其中m是介于2、3、4或6-24之间的整数,—COCH2O(CH2CH2O)n—其中n是介于2和24之间的整数;R′是氢、苄基或烷基,烷基可以是直链或支链;p是介于1和4之间的整数;Rn代表选择自H、烷氧基、苯甲氧基、醛、卤素、羧酸和—NO2的一个或多个成员,它直接附着在芳香环上或通过脂肪链附着。从这些化合物制备的可吸收聚合物对于药物传递、组织工程、组织粘接、粘着预防和其他可植入医疗器械非常有用。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐